Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Eingun James Song, MD, is the director of clinical research for Frontier Dermatology. 

Value of Utilizing Matching-Adjusted Indirect Comparisons (MAICs) in Psoriasis

In this episode, "Value of Utilizing Matching-Adjusted Indirect Comparisons (MAICs) in Psoriasis," the expert dermatologists explore the methodology behind matching adjusted indirect comparisons and their practical value in guiding evidence based treatment decisions for plaque psoriasis.

The panel opens by establishing that while head to head clinical trials remain the gold standard for comparing therapies, they are not always available. In their absence, matching adjusted indirect comparisons offer a more statistically rigorous alternative to simply comparing results across separate trials. The methodology is explained clearly: when patient level data is available for one drug and only aggregate mean demographic data is available for another, the patient level dataset can be adjusted and matched to the population characteristics of the comparator drug. This process accounts for known variables that can influence treatment outcomes, such as prior biologic exposure, disease severity, and the prevalence of psoriatic arthritis in the study population, resulting in a more balanced and meaningful comparison between the two therapies.

The panel emphasizes that matching adjusted indirect comparisons are not only valuable to manufacturers seeking to demonstrate their drug's performance to payers, but also serve as an important clinical decision making tool for dermatologists navigating treatment sequencing without direct comparative data. The discussion concludes with the panel reinforcing that patients who receive the most effective drug first tend to achieve better long term outcomes than those who cycle through multiple therapies, making the ability to identify a preferred agent through indirect comparison models a meaningful advantage in optimizing patient care.

The next episode in this series, "Evaluating Psoriasis Therapies using MAICs," features the panelists advancing their conversation on psoriasis and focusing on recent MAIC analyses comparing key IL-23 inhibitors and other biologic classes, highlighting how these indirect comparisons have demonstrated statistically significant efficacy differences across PASI endpoints and have since been validated by dedicated head to head clinical trials.

Videos

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Video Series

Analyzing IL-23 Inhibitors in Psoriasis

This episode, titled "Analyzing IL-23 Inhibitors in Psoriasis," features panelists discussing the future of IL-23 targeted therapies and the practical considerations surrounding the anticipated shift toward oral treatment options in plaque psoriasis.

The panel opens by surveying the emerging therapeutic pipeline, noting that most innovations continue to target the IL-23 pathway either directly or indirectly, underscoring the cytokine's central role in psoriasis pathogenesis. Key agents discussed include an oral macrocyclic peptide IL-23 receptor blocker, which directly binds the receptor rather than the cytokine and has demonstrated complete skin clearance in approximately half of patients at 24 weeks, a level of efficacy described as unprecedented for an oral therapy and comparable to leading biologics. Two next generation TYK2 inhibitors are also highlighted, offering higher binding affinity and selectivity than existing options and indirectly antagonizing IL-23 signaling with more rapid and deeper responses. Additionally, a monoclonal antibody called ORKA-001 is discussed, notable for its half-life approximately four times greater than risankizumab and its potential for dosing intervals of every 6 to 12 months in responding patients.

From a safety standpoint, the panel notes that IL-23 targeted therapies continue to demonstrate a favorable profile, with only occasional mild adverse events such as upper respiratory tract infections or fungal infections.

The discussion then shifts to the practical implications of oral versus injectable IL-23 therapies in real world settings. The panel acknowledges that while clinical trials demonstrate strong efficacy for emerging oral agents, real world adherence remains an open question, with concerns around daily pill taking, administration requirements such as empty stomach dosing, and potential drug interactions. Injectable biologics are noted as having a relative adherence advantage given their infrequent dosing schedule and easier monitoring. The panel agrees that needle phobia, while real for some patients, affects a smaller population than commonly assumed, particularly when injections are spaced weeks or months apart. Ultimately, the panel expresses enthusiasm for expanded treatment options, emphasizing that real world evidence will be critical in determining how well emerging oral therapies perform outside of controlled trial settings.

In the next episode, "Value of Utilizing Matching-Adjusted Indirect Comparisons (MAICs) in Psoriasis," panelists will continue their discussion on psoriasis and highlight the methodology and clinical value of matching adjusted indirect comparisons as a rigorous statistical tool for comparing biologic therapies in the absence of head to head trial data, and how this evidence can inform treatment sequencing decisions in real world practice.

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know—whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include the US Food and Drug Administration (FDA) label expansion of 2 cystic fibrosis transmembrane conductance regulator (CFTR) modulator regimens and approval of Lilly’s orforglipron (Foundayo) for adults with obesity or overweight with weight-related medical problems, an indirect analysis comparing weight loss with oral semaglutide (Wegovy) versus orforglipron (Foundayo), new Clinical Practice Guidelines from the American Society of Hematology on the diagnosis and management of severe and very severe acquired aplastic anemia, and phase 3 VALOR trial data on brepocitinib in adults with dermatomyositis who had failed multiple prior treatments.

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here’s your quick dive into the top stories for the week of March 29, 2026—let’s jump in!

FDA Expands CFTR Modulator Labels, Covering ~95% of US Cystic Fibrosis Patients

On April 1, 2026, the FDA approved label expansions for a pair of CFTR modulator regimens, vanzacaftor/tezacaftor/ivacaftor (Alyftrek) and elexacaftor/tezacaftor/ivacaftor (Trikafta), broadening eligibility to an estimated 95% of people with CF in the United States. The expanded indications now encompass any 

 gene variant resulting in production of CFTR protein, in addition to variants previously identified as clinically or 

FDA Approves Orforglipron (Foundayo) As First Daily GLP-1 Pill Without Food, Water Restrictions

On April 1, 2026, the FDA approved Lilly’s orforglipron (Foundayo) for adults with obesity or overweight with weight-related medical problems. When used alongside a reduced-calorie diet and increased physical activity, orforglipron helps individuals lose excess body weight and keep the weight off. In the ATTAIN-1 clinical trial, adults taking orforglipron lost an average of 27 pounds on the highest dose.

Of note, the once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist can be taken any time of the day without restrictions on food and water intake.

Indirect Analysis Suggests Greater Weight Loss With Oral Semaglutide vs Orforglipron

On April 2, 2026, Novo Nordisk announced a population-adjusted indirect comparison presented at the Obesity Medicine Association 2026 found greater mean weight loss with oral semaglutide (Wegovy) than with orforglipron (Foundayo) in adults with obesity or overweight and at least 1 weight-related comorbidity, both without diabetes. The analysis, which came the day following orforglipron’s FDA approval for obesity, also suggested lower odds of treatment discontinuation due to adverse events, particularly gastrointestinal events, with oral semaglutide.

ASH Publishes Guidelines on Diagnosis and Management of Severe and Very Severe Acquired Aplastic Anemia

The American Society of Hematology (ASH)’s new Clinical Practice Guidelines on Diagnosis and Management of Severe and Very Severe Acquired Aplastic Anemia (AA) outline 33 recommendations and 4 good practice statements for children and adults. The document focuses on tools to improve diagnosis and treatment decisions, including expanded use of specialized blood and genetic tests, personalized initial treatment based on age and availability of a fully matched donor, the addition of eltrombopag to standard immunosuppressive therapy to improve blood cell counts, and earlier transition to second-line treatments after initial immunosuppression for patients who do not respond or relapse.

“It’s critical to definitively diagnose individuals with aplastic anemia to ensure that they are promptly connected to appropriate treatment,” said Phil Scheinberg, MD, head of the division of hematology at Hospital Beneficência Portuguesa Hospital in São Paulo, and chair of the ASH 2026 Guidelines for the Diagnosis and Management of Severe and Very Severe Acquired Aplastic Anemia. “We hope these guidelines will not only improve patient outcomes but also expand access to diagnostic testing and catalyze broader global access to transplant and immunosuppressive therapies.”

VALOR: Brepocitinib AAD Data Support Priority Review for Dermatomyositis

Brepocitinib, an investigational oral therapy targeting TYK2 and JAK1 produced rapid, sustained improvements in global disease activity, skin disease, itch, and physical function in adults with dermatomyositis who had failed multiple prior treatments, prompting the FDA to grant the therapy Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date in the third quarter of 2026. The new data from the phase 3 VALOR trial were published March 28, 2026, in the 

 and simultaneously presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting held in Denver, Colorado, from March 27-31.

Articles

FDA label expansions for vanzacaftor/tezacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor broaden CFTR modulator eligibility to ~95% of US cystic fibrosis patients by covering any protein-producing CFTR variant. Lilly’s orforglipron, a once-daily small-molecule oral GLP-1RA, gained FDA approval for obesity/overweight without food or water restrictions, with ATTAIN-1 showing 27 lb mean loss at highest dose. An indirect comparison favored oral semaglutide for greater weight loss and fewer GI discontinuations. ASH issued comprehensive severe acquired aplastic anemia guidance. Phase 3 VALOR supported brepocitinib Priority Review in dermatomyositis.

Stay updated with the latest healthcare breakthroughs, including FDA actions and comparative weight loss drug data, in this week’s essential news roundup.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Hematology

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

The HCPFive: Top News for Healthcare Providers from the Week of 03/29

Jane M. Grant-Kels, MD, is the vice chair of the Department of Dermatology and founding director of the Cutaneous Oncology Center and Melanoma Programs and a professor of dermatology, pathology, and pediatrics at the University of Connecticut Health Center.

A session titled ‘The Pregnant Pause: How to Evaluate and Treat Your Pregnant Patients’ was presented at the 

2026 American Academy of Dermatology (AAD) Annual Meeting

One of the presenters of this session was Jane M. Grant-Kels, MD, the vice chair of the Department of Dermatology and founding director of the Cutaneous Oncology Center and Melanoma Programs and a professor of dermatology, pathology, and pediatrics at the University of Connecticut Health Center.

 interviewed Grant-Kels regarding some of the most important takeaways from this session. The following Q&A interview spotlights her responses:

Pregnancy presents a uniquely complex set of constraints for dermatologists such as limited evidence-based data and fetal safety concerns. In your view, what are the most common mistakes or gaps you see in how dermatologists currently approach the pregnant patient, and what does this session aim to address?

My area that I'm addressing is how to deal with melanocytic nevi and how to deal with melanoma. So during pregnancy, the woman's body changes. Obviously, her breasts enlarge, her abdomen enlarges, and melanocytic nevi on those locations can enlarge as well, but generally, melanocytic nevi do not change drastically during pregnancy. My advice is, if you have a melanocytic nevus and it's changing, you should check it with the dermatoscope, and if there are any changes that suggest malignancy, the lesion should be biopsied immediately.

Having said that, there's no suggestion that patients when pregnant have a higher incidence of developing melanoma. I also address the controversy about whether melanoma when it is developed during pregnancy has a worse prognosis, and that has been assumed in the past, because when women are pregnant, they are somewhat immunosuppressed. They have induced lymphangiogenesis and other angiogenesis…The evidence shows that when a woman is pregnant and if she does develop a melanoma, her prognosis is not different than if she were not pregnant. And so you treat them the same. So that is a sum of what I have to say to the audience.

Is there a general lack of clinical data, clinical trial data, regarding pregnant patients in the dermatology space, and is that the kind of thing that can be addressed?

 It's very hard to do studies on obstetricians don't like to share their pregnant patients for clinical trials, even if it's just observation and watching their moles. We did a study many years ago, and it took us a long time to get a significant number of pregnant women because it was very hard to induce obstetricians to refer patients, even though we were just examining their backs and their nevi on their backs. So yes, there is a paucity, and obviously clinical trials are very rarely done in pregnant women because of the fact that they're obviously they're carrying a fetus.

You wouldn't want to expose them to drugs unnecessarily, so that is an issue. And because of that, and because when a woman is pregnant and does develop a melanoma, especially if it's a high risk deep melanoma, those tend to get reported as case reports. So there are years of people under the false impression that pregnancy increased your risk of melanoma because of those case reports, when, in fact, when large studies are done looking at pregnant versus non pregnant women with control groups, there is no increased incidence of melanoma during pregnancy.

Among patients, are there concerns that you've seen among pregnant patients related to concerns such as these?

 Patients notice that their nevi on their breasts and abdomen change. They can see the those areas, and their skin gets enlarged, so the nevi get expanded. The pregnant women also develop some hyperpigmentation. Their areola, the nipple gets darker. They can develop a linear nigra, which is a hyperpigmentation on their abdomen in a vertical area, and so patients notice that there are changes in their skin. They get stretch marks, then patients get very nervous if you're going to inject a numbing medication to remove a lesion, because they always are concerned that it might hurt their baby. But there is very good evidence that to do a biopsy in a pregnant woman is perfectly safe.

Are there any other major takeaways from this session that you really hope clinicians walk away with?

 The big takeaway is that nevi don't change significantly physiologically during pregnancy. So if you have a nevus, if you have a patient who happens to be pregnant, and they're one of their nevi is changing. If you look at it with your dermatoscope and you see any features that suggest potential melanoma, you shouldn't assume those changes are physiologic. You should biopsy that patient, because just because they're pregnant doesn't mean they have an increased incidence of melanoma.

But it also doesn't mean they cannot get a melanoma because they can. There's an increased incidence of melanoma in women of childbearing age in general, that's unrelated to pregnancy, so the two can occur together. In the past, there was delay in diagnosis because many people felt that nevi changed physiologically during pregnancy. I would never make that assumption. If a nevus is changing and any features of malignancy are noted, take that lesion off. The other thing is, if you have a pregnant woman and she does develop a melanoma, you should educate her to the fact that her prognosis is not altered by her pregnancy. And especially if she has a relatively thin melanoma, she's going to do fine and it's not going to hurt her fetus.

The quotes contained in this summary were edited for clarity.

Grant-Kels J, et al. F001 The Pregnant Pause: How to Evaluate and Treat Your Pregnant Patients. Sesson presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.

Pregnancy-related skin changes often prompt concern about evolving nevi, particularly on the breasts and abdomen where stretching and hyperpigmentation occur. Physiologic nevus alteration is usually minimal; suspicious evolution warrants dermoscopy and prompt biopsy, which is considered safe with local anesthetic. Epidemiologic data do not show increased melanoma incidence during pregnancy, and outcomes for pregnancy-associated melanoma mirror nonpregnant controls despite theoretical immunologic and angiogenic shifts. Limited prospective data reflect ethical and referral barriers, amplifying reliance on case reports. Clinician education should prevent diagnostic delay.

This Q&A interview with Grant-Kels highlights takeaways from her session on managing the needs of patients in dermatology practicers who are pregnant.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Advice for Evaluating Pregnant Patients in Dermatology, With Jane M. Grant-Kels, MD

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

Diabetes Dialogue: FDA Approves Novo Nordisk’s Insulin Icodec-abae (Awiqli) for T2D

 approved Novo Nordisk’s insulin icodec-abae under the name Awiqli for patients with 

In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, highlight the FDA approval of once-weekly insulin icodec, emphasizing its significance as a major advancement in insulin therapy. They begin by addressing practical considerations, including its high concentration (U-700) and the implications for dosing, noting that weekly administration necessitates substantially higher unit doses compared with daily basal insulin.

The discussion focuses on dosing strategy, particularly the need to scale weekly doses approximately sevenfold relative to daily regimens, as well as the rationale for an initial loading dose of 1.5 times the calculated weekly requirement to more rapidly achieve steady state. Isaacs underscores the pharmacokinetic basis for this approach, given the drug’s long half-life and delayed time to steady state, while also noting the constraints of dosing in 10-unit increments.

Bellini and Isaacs explore the clinical implications of once-weekly insulin, with particular attention to adherence and treatment burden. Bellini emphasizes the potential benefit for insulin-naive patients and those struggling with daily injection adherence, framing weekly insulin as a means to significantly reduce injection frequency and improve consistency. Isaacs expands on this, arguing that reduced dosing frequency may mitigate missed doses and glycemic variability, especially in patients with irregular routines. Both highlight the flexibility afforded by the long half-life, allowing for minor deviations in dosing timing without substantial impact on glycemic control.

The conversation also addresses potential risks, including delayed titration and the possibility of over-basalization, particularly in patients with fluctuating nutritional intake or socioeconomic instability. They stress the importance of careful patient selection and monitoring, given the longer interval required to adjust doses.

Reviewing clinical trial data from the ONWARDS phase 3 program, the hosts note that once-weekly insulin demonstrated modestly greater A1C reduction compared with daily basal insulin in treat-to-target trials, reinforcing the hypothesis that improved adherence may translate into better glycemic outcomes.

They further discuss implementation considerations across care settings, highlighting potential advantages for older adults, caregivers, and patients in long-term care, where reduced injection burden may improve safety, independence, and medication management. The episode also touches on current regulatory limitations, noting that while approval is presently limited to type 2 diabetes in the United States, ongoing studies may expand its indication to type 1 diabetes, with off-label use anticipated in select cases.

The hosts conclude by situating weekly insulin within the broader therapeutic landscape, emphasizing renewed innovation in insulin development alongside incretin-based therapies. They note that additional agents in development may soon expand options within this class, signaling a meaningful shift in the management of diabetes toward more patient-centered, lower-burden treatment paradigms.

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Novo Nordisk. Awiqli approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes. March 26, 2026. Accessed April 3, 2026. 

https://ml-eu.globenewswire.com/Resource/Download/cb9dda59-1286-4718-a7e5-4256e2397b0c

Kunzmann K. FDA Approves Insulin Icodec (Awiqli) as First Once-Weekly Basal Insulin for Type 2 Diabetes. 

. March 26, 2026. Accessed April 3, 2026. 

https://www.hcplive.com/view/fda-approves-awiqli-insulin-icodec-first-once-weekly-basal-insulin-for-type-2-diabetes

Podcasts

This episode covers the March 26th approval of Awiqli for T2D, highlighting its high concentration and once-weekly administration.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Mardi Gomberg-Maitland, MD, MSc, is the director of the pulmonary hypertension program, chief clinical research officer at the Office of Clinical Research SMHS, and a professor of medicine at George Washington University.

Gomberg-Maitland addresses sotatercept’s capacity to improve pulmonary vascular and cardiac endpoints in patients with CpcPH-HFpEF.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

CADENCE: Sotatercept Reduces PVR in CpcPH-HFpEF, With Mardi Gomberg-Maitland, MD, MSc

Sayna Norouzi, MD, is an assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center

Norouzi discussed the remaining challenges that come with having evolving treatment options and a robust patient population in IgAN.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

New Therapeutic Options Raise More Questions for IgA Nephropathy Treatment, With Sayna Norouzi, MD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Catch up on the most impactful trial readouts to come out of ACC 2026.

Arrhythmia

Cardiomyopathy

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Dyslipidemia

ACC 2026: Phase 2/3 Trials to Know

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

This review of new data on psoriasis treatments from AAD 2026 highlights several key trials.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

AAD 2026: 6 Psoriasis Trials to Know

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Catch up on the guideline updates, trial news, and featured content from March 2026. 


Chronic Kidney Disease

5 Nephrology Headlines You Missed in March 2026

This episode discusses the recently released algorithm for T2D from the American Association of Clinical Endocrinology.

Diabetes Dialogue: 2026 AACE Guidelines for Type 2 Diabetes

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Check out 6 FDA decisions to watch in Q2 2026, listed chronologically by expected decision date.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Q2 2026 Preview: 6 FDA Decisions to Watch

Luke Laffin, MD, is the co-director of the Center for Blood Pressure Disorders, medical director of cardiac rehabilitation, and associate professor of medicine at Cleveland Clinic.

Laffin discusses results from the Kardinal study, which investigated a single dose of tonlamarsen followed by placebo against monthly tonlamarsen treatment in hypertension.

Tonlamarsen Lowers Angiotensinogen, Mixed Results for Blood Pressure, With Luke Laffin, MD

In this AAD interview, Song highlights how he views the potential benefit of amlitelimab in light of discontinuing rocatinlimab.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Discussing Future of Amlitelimab, OX40/OX40L Treatment, With Eingun James Song, MD

Read 6 updates from the meeting that clinicians managing atopic dermatitis should know.

Latest News

Value of Utilizing Matching-Adjusted Indirect Comparisons (MAICs) in Psoriasis

Analyzing IL-23 Inhibitors in Psoriasis

The HCPFive: Top News for Healthcare Providers from the Week of 03/29

Advice for Evaluating Pregnant Patients in Dermatology, With Jane M. Grant-Kels, MD

Diabetes Dialogue: FDA Approves Novo Nordisk’s Insulin Icodec-abae (Awiqli) for T2D